- Home
- OVID vs BCAB Comparison
OVID vs BCAB Comparison
Compare OVID & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- BCAB
- Stock Information
- Founded
- OVID 2014
- BCAB 2007
- Country
- OVID United States
- BCAB United States
- Employees
- OVID N/A
- BCAB N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- OVID Health Care
- BCAB Health Care
- Exchange
- OVID Nasdaq
- BCAB Nasdaq
- Market Cap
- OVID 24.0M
- BCAB 27.0M
- IPO Year
- OVID 2017
- BCAB 2020
- Fundamental
- Price
- OVID $0.29
- BCAB $0.43
- Analyst Decision
- OVID Strong Buy
- BCAB Buy
- Analyst Count
- OVID 6
- BCAB 2
- Target Price
- OVID $3.03
- BCAB $1.00
- AVG Volume (30 Days)
- OVID 376.8K
- BCAB 538.7K
- Earning Date
- OVID 05-20-2025
- BCAB 05-06-2025
- Dividend Yield
- OVID N/A
- BCAB N/A
- EPS Growth
- OVID N/A
- BCAB N/A
- EPS
- OVID N/A
- BCAB N/A
- Revenue
- OVID $566,000.00
- BCAB $11,000,000.00
- Revenue This Year
- OVID N/A
- BCAB N/A
- Revenue Next Year
- OVID $36.11
- BCAB N/A
- P/E Ratio
- OVID N/A
- BCAB N/A
- Revenue Growth
- OVID 44.39
- BCAB N/A
- 52 Week Low
- OVID $0.24
- BCAB $0.24
- 52 Week High
- OVID $3.43
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- OVID 39.90
- BCAB 51.43
- Support Level
- OVID $0.28
- BCAB $0.43
- Resistance Level
- OVID $0.33
- BCAB $0.58
- Average True Range (ATR)
- OVID 0.03
- BCAB 0.06
- MACD
- OVID 0.00
- BCAB 0.00
- Stochastic Oscillator
- OVID 16.97
- BCAB 45.21
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.